Status:
UNKNOWN
Panitumumab, Cisplatin, and Pelvic Radiation Therapy in Treating Patients With Stage IB, Stage II, or Stage III Cervical Cancer
Lead Sponsor:
Medical University Innsbruck
Conditions:
Cervical Cancer
Eligibility:
FEMALE
Phase:
PHASE2
Brief Summary
RATIONALE: Monoclonal antibodies, such as panitumumab, can block tumor growth in different ways. Some block the ability of tumor cells to grow and spread. Others find tumor cells and help kill them or...
Detailed Description
OBJECTIVES: Primary * To assess the activity of concurrent panitumumab and cisplatin chemoradiotherapy in patients with stage IB-IIIB, KRAS-wild type (KRAS\^wt) cervical cancer, in terms of progress...
Eligibility Criteria
Inclusion
- DISEASE CHARACTERISTICS:
- Histologically confirmed cervical cancer, including the following subtypes:
- Squamous small-cell or large-cell carcinoma
- Adenosquamous cell carcinoma
- Adenocarcinoma
- Keratinizing or non-keratinizing carcinoma
- Stage IB-IIIB disease
- No para-aortic lymph node metastases or clinical indication for para-aortic field irradiation
- No predominant and clinically effective neuroendocrine tumor cell differentiation
- PATIENT CHARACTERISTICS:
- WH0 performance status 0-2
- Serum creatinine clearance \> 50 mL/min
- No other prior or current malignancy within the past 5 years except adequately treated nonmelanoma skin cancer or carcinoma in-situ of the cervix
- No acute life-threatening vaginal hemorrhage (requiring emergency irradiation or RBC transfusion)
- PRIOR CONCURRENT THERAPY:
- Not specified
Exclusion
Key Trial Info
Start Date :
February 1 2010
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
Estimated Enrollment :
50 Patients enrolled
Trial Details
Trial ID
NCT01158248
Start Date
February 1 2010
Last Update
July 9 2010
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Innsbruck Universitaetsklinik
Innsbruck, Austria, A-6020